ARWR
$57.57
Arrowhead Pharmaceuticals, Inc.
Recent News
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of Billionaire Ken Fisher’s 15 Most Notable Moves for 2026. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a relatively recent addition to the 13F portfolio of Fisher Asset Management. The fund first disclosed a stake in the firm in filings for the second quarter of 2024, comprising close to 12,000 shares […]
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires. On February 5, Arrowhead Pharmaceuticals achieved a strategic turning point in FQ1 2026, transitioning into a commercial-stage organization following the US FDA approval of its first medicine, REDEMPLO (plozasiran). This siRNA therapeutic, designed to treat familial chylomicronemia syndrome/FCS, […]
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead
Arrowhead Pharmaceuticals (NASDAQ:ARWR) outlined a slate of expected clinical data updates during a discussion at the Leerink Partners Global Healthcare Conference in Miami, with management pointing to multiple readouts concentrated in the third quarter and additional updates expected in the second
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined a busy slate of clinical catalysts and a growing commercial footprint during a presentation at TD Cowen’s 46th Annual Healthcare Conference, emphasizing a pipeline that management said includes roughly 21 or 22 drug candidates in clinical s